Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2785–2808 of 13,638 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Renal Cell Carcinoma, Hypertension, Melanoma, Cancer
Interventions: Ambulatory Blood Pressure Measurement; Diagnostic Test
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Malignant Melanoma
Interventions: GM-CSF; Drug
Lead sponsor: Mt. Sinai Medical Center, Miami; Other
Eligibility: 16 Years to 90 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Miami Beach, Florida • Atlanta, Georgia

Conditions: Psoriatic Arthritis
Interventions: Diet 1, Diet 2; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Ixabepilone, Paclitaxel, Cyclophosphamide, Doxorubicin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 10
States / cities: Palm Springs, California • Coral Spring, Florida • Davie, Florida + 7 more

Conditions: Breast Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Abraxane, Alimta; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Vitiligo
Interventions: ATI-50002 topical solution; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Encinitas, California • Los Angeles, California • Worcester, Massachusetts + 2 more

Conditions: Pyoderma Gangrenosum
Interventions: Dehydrated human amnion/chorion membrane; Biological
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Metairie, Louisiana • New Orleans, Louisiana

Conditions: Abnormalities, Radiation-Induced
Interventions: Not listed
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 48 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Sarcoidosis, Granuloma Annulare
Interventions: Deucravacitinib; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV Infections, Lipoatrophy
Interventions: NucleomaxX, NucleomaxX placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 20 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Breast Biopsy Procedure, Carboplatin, Cyclophosphamide, Darolutamide, Doxorubicin, Epirubicin, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Surgical Procedure, Ultrasound Imaging; Procedure · Drug · Biological
Lead sponsor: Vandana Abramson; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Dermatitis, Atopic
Interventions: Nemolizumab, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years to 54 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 64
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 53 more

Conditions: Ovarian Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer, Gastrointestinal Cancer, Triple Negative Breast Cancer, Ovarian Carcinoma
Interventions: TJ004309; Drug
Lead sponsor: I-Mab Biopharma US Limited; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Tucson, Arizona • Whittier, California • Newark, Delaware + 12 more

Conditions: Head and Neck Cancer
Interventions: Not listed
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Bevacizumab; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Elastography, Multigated Acquisition Scan, Nivolumab, Sargramostim; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2033
U.S. locations: 763
States / cities: Birmingham, Alabama • Kingman, Arizona • Little Rock, Arkansas + 494 more

Conditions: Lymphoma
Interventions: proteomic profiling; Genetic
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 423 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2010
U.S. locations: 4
States / cities: Stanford, California • Baltimore, Maryland • Bethesda, Maryland + 1 more

Conditions: Lung Cancer, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Estrogen Receptor Breast Cancer
Interventions: entinostat, Erlotinib, Exemestane; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee

Conditions: Neoplasms, Breast
Interventions: lapatinib, paclitaxel, trastuzumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2019
U.S. locations: 14
States / cities: Roswell, Georgia • Joliet, Illinois • Detroit, Michigan + 10 more

Conditions: Early Stage Breast Cancer
Interventions: POWER-remote, Self-directed; Behavioral
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Musculoskeletal Complication, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Therapy-Related Toxicity
Interventions: Quality-of-Life Assessment, Questionnaire Administration, Medical Chart Review; Procedure · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Granulomatous, Mastitis
Interventions: Not listed
Lead sponsor: Granulomatous Mastitis Working Group; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage I
Interventions: Pencil Beam Scanning Proton Therapy; Radiation
Lead sponsor: Covenant Health Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Skin Cancer
Interventions: Education, Action Plan, UV Photo, MC1R Test; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 528 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease

Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma

Diet Interventions in Psoriatic Arthritis

Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer

Abraxane and Alimta in Advanced Solid Tumors

A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo

A Novel Therapeutic Treatment of Pyoderma Gangrenosum

Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients

Tyrosine Kinase 2 (TYK2) for GA and CS

Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

TEST: Registry for Endoscopic Head and Neck Surgery

Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Serum Protein Patterns in Participants With Mycosis Fungoides/Cutaneous T-Cell Lymphoma, Psoriasis, or Normal Skin

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

POWER-remote Weight Loss Program in Early Stage Breast Cancer

Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer

Granulomatous Mastitis Current Approach and Treatment

Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy

Undergraduate Skin Cancer Prevention Trial